Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,715
  • Shares Outstanding, K 10,318
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,630 K
  • 60-Month Beta 0.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.77

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.36 +23.86%
on 12/03/19
1.75 -3.43%
on 11/12/19
+0.07 (+4.32%)
since 11/08/19
3-Month
1.34 +26.12%
on 10/15/19
1.93 -12.44%
on 09/11/19
+0.12 (+7.64%)
since 09/10/19
52-Week
1.34 +26.12%
on 10/15/19
9.44 -82.10%
on 01/15/19
-0.44 (-20.66%)
since 12/10/18

Most Recent Stories

More News
Adial Completes Final Packaging of AD04 for Shipment to Phase 3 Trial Clinical Sites

CHARLOTTESVILLE, VA / ACCESSWIRE / October 29, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments...

ADIL : 1.69 (+4.32%)
ADILW : 0.09 (unch)
Adial Pharmaceuticals Receives Notice of Allowance from US Patent and Trademark Office for Patent for the Treatment of Alcohol Use Disorder in Patients Identified Using a Molecular Genetic Biomarker

CHARLOTTESVILLE, VA / ACCESSWIRE / October 17, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.69 (+4.32%)
ADILW : 0.09 (unch)
Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.69 (+4.32%)
Adial Files Clinical Trial Application to Commence Phase 3 Trial

CHARLOTTESVILLE, VA / ACCESSWIRE / October 1, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.69 (+4.32%)
ADILW : 0.09 (unch)
Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.69 (+4.32%)
Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...

ADIL : 1.69 (+4.32%)
ADILW : 0.09 (unch)
Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

Application for pediatric investigation plan waiver validated by European Medicines Agency

ADIL : 1.69 (+4.32%)
Adial Pharmaceuticals' Chief Executive Officer to be Featured Live on Cheddar's ''Closing Bell''

CHARLOTTESVILLE, VA / ACCESSWIRE / August 6, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...

ADIL : 1.69 (+4.32%)
ADILW : 0.09 (unch)
Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization

Adial Reaffirms on Track to Commence Phase 3 Trial in Q3 2019

ADIL : 1.69 (+4.32%)
Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder

CHARLOTTESVILLE, VA / ACCESSWIRE / May 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today...

ADIL : 1.69 (+4.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ADIL with:

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

2nd Resistance Point 1.78
1st Resistance Point 1.74
Last Price 1.69
1st Support Level 1.61
2nd Support Level 1.52

See More

52-Week High 9.44
Fibonacci 61.8% 6.35
Fibonacci 50% 5.39
Fibonacci 38.2% 4.43
Last Price 1.69
52-Week Low 1.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar